Amycretin vs Lixisenatide

Amycretin is an experimental drug that combines two hormone-mimicking signals (amylin and GLP-1) to help control blood sugar and weight, but it has not yet been approved by the FDA for any use. Lixisenatide, sold as Adlyxin or Soliqua, is an FDA-approved GLP-1-only treatment for type 2 diabetes that patients inject once daily.

AI summary of the sources below.